KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Liabilities from Discontinued Operations (2025)

Novavax has reported Liabilities from Discontinued Operations over the past 1 years, most recently at 47869000.0 for Q4 2025.

  • Quarterly results put Liabilities from Discontinued Operations at 47869000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 47869000.0 (changed N/A YoY), and the annual figure for FY2025 was 47869000.0, changed.
  • Liabilities from Discontinued Operations for Q4 2025 was 47869000.0 at Novavax, down from 51435000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for NVAX hit a ceiling of 51435000.0 in Q3 2025 and a floor of 47869000.0 in Q4 2025.